Cryosite Limited provides outsourced clinical trials logistic services in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.35|
|52 Week High||AU$0.16|
|52 Week Low||AU$0.47|
|1 Month Change||-13.58%|
|3 Month Change||-12.50%|
|1 Year Change||45.83%|
|3 Year Change||n/a|
|5 Year Change||79.49%|
|Change since IPO||-20.45%|
Recent News & Updates
|CTE||AU Life Sciences||AU Market|
Return vs Industry: CTE exceeded the Australian Life Sciences industry which returned -3.4% over the past year.
Return vs Market: CTE exceeded the Australian Market which returned 19.3% over the past year.
Stable Share Price: CTE is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: CTE's weekly volatility (9%) has been stable over the past year.
About the Company
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport solutions, and biological storage services to the clinical trial and research industry.
Cryosite Fundamentals Summary
|CTE fundamental statistics|
Is CTE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CTE income statement (TTM)|
|Cost of Revenue||AU$4.13m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.013|
|Net Profit Margin||6.51%|
How did CTE perform over the long term?See historical performance and comparison
Is Cryosite undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CTE's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CTE's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CTE is good value based on its PE Ratio (26.2x) compared to the Global Life Sciences industry average (46x).
PE vs Market: CTE is poor value based on its PE Ratio (26.2x) compared to the Australian market (19.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CTE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CTE is overvalued based on its PB Ratio (45.3x) compared to the AU Life Sciences industry average (4.9x).
How is Cryosite forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cryosite has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Cryosite performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CTE has high quality earnings.
Growing Profit Margin: CTE's current net profit margins (6.5%) are lower than last year (16.6%).
Past Earnings Growth Analysis
Earnings Trend: CTE's earnings have grown significantly by 35.4% per year over the past 5 years.
Accelerating Growth: CTE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: CTE had negative earnings growth (-55.9%) over the past year, making it difficult to compare to the Life Sciences industry average (59.8%).
Return on Equity
High ROE: CTE's Return on Equity (172.8%) is considered outstanding.
How is Cryosite's financial position?
Financial Position Analysis
Short Term Liabilities: CTE's short term assets (A$7.3M) exceed its short term liabilities (A$3.5M).
Long Term Liabilities: CTE's short term assets (A$7.3M) do not cover its long term liabilities (A$18.1M).
Debt to Equity History and Analysis
Debt Level: CTE is debt free.
Reducing Debt: CTE has not had any debt for past 5 years.
Debt Coverage: CTE has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CTE has no debt, therefore coverage of interest payments is not a concern.
What is Cryosite current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CTE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CTE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CTE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CTE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: CTE is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CTE's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. John Hogg has been Chief Executive Officer at Cryosite Limited since October 15, 2020. Mr. Hogg joined Cryosite in July 2018 and was promoted to General Manager of Operations on the 1st December 2019....
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD249.72K) is about average for companies of similar size in the Australian market ($USD300.24K).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
Experienced Board: CTE's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.
Cryosite Limited's employee growth, exchange listings and data sources
- Name: Cryosite Limited
- Ticker: CTE
- Exchange: ASX
- Founded: 1999
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$17.083m
- Shares outstanding: 48.81m
- Website: https://www.cryosite.com
Number of Employees
- Cryosite Limited
- 13a Ferndell Street
- South Granville
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/15 07:02|
|End of Day Share Price||2021/10/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.